AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?
Despite a bumpy takeoff, AbbVie has some big plans for Vraylar, the blockbuster schizophrenia and bipolar drug it snapped up from Allergan a couple of years ago. Looking ahead, CEO Richard Gonzalez says a supplemental approval in major depressive disorder could send sales into the stratosphere — that is, if the FDA is willing to get on board.
As promised in the recent Q4 call, AbbVie has submitted its sNDA filing for Vraylar as an add-on therapy for MDD, one of the most common mental disorders in the US. The company’s hoping for a regulatory decision by the end of the year — and if all goes well, Gonzalez says the indication could push peak sales past the $4 billion mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.